Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 123.03M P/E - EPS this Y 65.60% Ern Qtrly Grth -
Income -49.29M Forward P/E -8.26 EPS next Y -14.40% 50D Avg Chg -1.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg 39.00%
Dividend N/A Price/Book 0.73 EPS next 5Y - 52W High Chg -45.00%
Recommedations 1.50 Quick Ratio 45.52 Shares Outstanding 25.64M 52W Low Chg 216.00%
Insider Own 22.62% ROA -17.48% Shares Float 12.55M Beta -
Inst Own 84.41% ROE -23.28% Shares Shorted/Prior 1.97M/2.16M Price 2.81
Gross Margin - Profit Margin - Avg. Volume 582,543 Target Price 58.33
Oper. Margin - Earnings Date Nov 12 Volume 112,276 Change -3.44%
About Talaris Therapeutics, Inc.

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.

Talaris Therapeutics, Inc. News
11/14/24 Tourmaline Bio to Host Investor Day on Tuesday, December 10, 2024
11/12/24 Tourmaline Bio, Inc. Reports Third Quarter Financial Results
11/07/24 Tourmaline Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights
10/31/24 Tourmaline Bio to Present at Upcoming Investor Conferences
10/15/24 Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November 1, 2024
10/11/24 Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress
10/08/24 Tourmaline Bio Announces Formation of Cardiovascular Scientific Advisory Board
08/08/24 Bullish Tourmaline Bio Insiders Loaded Up On US$643.3k Of Stock
08/08/24 Tourmaline Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights
08/02/24 Tourmaline Bio Presents Phase 2 TRANQUILITY Study Design at American Society of Preventive Cardiology (ASPC) Congress 2024
06/27/24 Tourmaline Bio Announces the Promotion of Ryan Robinson to Chief Financial Officer
05/23/24 Tourmaline Bio to Present at the Jefferies Global Healthcare Conference
05/16/24 Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial
05/13/24 Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights
04/02/24 Avalo Therapeutics Appoints Biotech Leaders to Board of Directors
03/19/24 Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
02/01/24 Tourmaline Bio to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
01/29/24 Tourmaline Bio Announces Closing of $172.5 Million Public Offering of Common Stock, Including Full Exercise of the Underwritersโ€™ Option to Purchase Additional Shares
01/25/24 Tourmaline Bio Announces Pricing of Public Offering of Common Stock
01/24/24 Tourmaline Bio Announces Proposed Public Offering of Common Stock
TRML Chatroom

User Image Trader2004 Posted - 10/31/24

@cheetohottaki @TheBigGame Want a good bio long? Don't trust markets right now can buy lower...$TRML after PFE 40 b buyout of $SGEN...Ceo becomes chairman of TRML...Look who is presenting data 11/1...This company will be in the 100s

User Image SlapDatAsk4 Posted - 1 month ago

$TRML c'mon 30's.

User Image Trader2004 Posted - 1 month ago

@yus37 Few others i'm long because of recent hires...3 ex $HZNP execs joined SGMT team last 18 mos....$TRML is self explanatory when $SGEN Ceo takes the chairman pos after 40 b buyout...

User Image briefingcom Posted - 1 month ago

$TRML: Tourmaline Chief Medical Officer to resign https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20241011061913TRML&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

User Image OpenOutcrier Posted - 1 month ago

$TRML (-5.4% pre) Tourmaline Bio (TRML) to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress - SI https://ooc.bz/l/44565

User Image RazorETC_F150Lightning Posted - 1 month ago

$TRML does this thing actually pay a yearly dividend?

User Image AlexPreda Posted - 1 month ago

$TRML 30$ soon!

User Image Justy_Nuff Posted - 1 month ago

$TRML

User Image Trader2004 Posted - 1 month ago

@donutfish 9 m os...Easy to manipulate...Look at $TRML did same bs...Then straight up 9-26

User Image Justy_Nuff Posted - 1 month ago

$TRML it touched $28 this morning... Going to 30

User Image Justy_Nuff Posted - 09/30/24

$TRML

User Image Shabba777 Posted - 09/26/24

$TRML this thing pays 60% dividend?!

User Image RazorETC_F150Lightning Posted - 09/25/24

$TRML what did I miss here? ๐Ÿ˜

User Image StockInvest_us Posted - 09/23/24

Signal alert: $TRML - Overbought Trend Short (Overvalued) https://stockinvest.us/l/l17W24aoox

User Image gothedistance Posted - 1 month ago

@Davedaman96 What dividend? $TRML

User Image Saspin Posted - 2 months ago

$TRML here we go ๐Ÿš€๐Ÿš€๐Ÿš€๐Ÿš€

User Image RazorETC_F150Lightning Posted - 2 months ago

$TRML when do we get paid?

User Image vu_jade Posted - 2 months ago

$TRML nice recovery going on

User Image Himel92 Posted - 2 months ago

The Last month Performance for $TRML Opening Price: $14.42 Closing Price: $15.35 Highest Price: $18.56 Lowest Price: $13.03 Percentage Change: 6.45% Data analyst: AITX

User Image Davedaman96 Posted - 2 months ago

$TRML Like the dividend. Small float. A nudge up is coming soon.

User Image Davedaman96 Posted - 2 months ago

$TRML $AMZN $GME $NVDA Check out $TRML . dividend yidld is amazing!

User Image Ewolf17 Posted - 2 months ago

$TRML

User Image CEOBuysDisclosures Posted - 2 months ago

$TRML CEO purchased 1,779 shares at $14.85 for a total of $26,418. Kulkarni Sandeep Chidambar now owns 7,000 shares. https://ceo-buys.com

User Image Ewolf17 Posted - 2 months ago

$TRML

User Image Ewolf17 Posted - 2 months ago

$TRML https://www.tickerreport.com/banking-finance/11836742/tourmaline-bio-inc-nasdaqtrml-receives-55-60-consensus-target-price-from-analysts.html

User Image Ewolf17 Posted - 3 months ago

$TRML Great potential here

User Image CEOBuysDisclosures Posted - 3 months ago

$TRML CEO purchased 5,221 shares at $13.79 for a total of $71,998. Kulkarni Sandeep Chidambar now owns 5,221 shares. https://ceo-buys.com

User Image StockInvest_us Posted - 3 months ago

Signal alert: $TRML - PivotPoint bottom https://stockinvest.us/l/lS13sNSN8b

User Image Fullratio Posted - 3 months ago

$TRML equity has soared by 128% year-on-year but it is down by 4.5% since the previous quarter: https://fullratio.com/stocks/nasdaq-trml/tourmaline-bio

User Image DonCorleone77 Posted - 3 months ago

$TRML Tourmaline Bio reports Q2 EPS (68c), consensus (71c) "The second quarter of 2024 was another period of strong execution by Tourmaline, including the dosing of the first patient in the Phase 2 TRANQUILITY trial. This represents an important milestone in our pacibekitug clinical development plan, where multiple converging lines of evidence from human genetic studies, epidemiological studies, and mechanistic experiments support the therapeutic potential of IL-6 inhibition for millions of patients with cardiovascular diseases," said Sandeep Kulkarni, MD, Co-Founder and Chief Executive Officer of Tourmaline. "Along with our ongoing clinical development efforts in TED, the TRANQUILITY trial provides us with two high-conviction paths to unlock major value creation as we approach key data readouts in 2025."

Analyst Ratings
HC Wainwright & Co. Buy Aug 12, 24
HC Wainwright & Co. Buy May 14, 24
Truist Securities Buy Mar 25, 24
Jefferies Buy Mar 20, 24
HC Wainwright & Co. Buy Mar 20, 24
Jefferies Buy Dec 15, 23
Truist Securities Buy Nov 17, 23
Guggenheim Buy Oct 31, 23
Piper Sandler Overweight Oct 25, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Kulkarni Sandeep Chidambar CEO CEO Nov 17 Buy 16.99 4,000 67,960 729,735 11/20/23
Thiara Parvinder Director Director Nov 17 Buy 17.31 1,000 17,310 83,782 11/20/23
Castelein Caley Director Director Oct 25 Buy 13.31 20,000 266,200 516,519 10/27/23
Kulkarni Sandeep Chidambar CEO CEO Oct 24 Buy 11.47 9,650 110,686 725,735 10/26/23
KANTOFF AARON Director Director Oct 24 Buy 11.86 7,500 88,950 45,391 10/26/23
Thiara Parvinder Director Director Oct 24 Buy 11.39 7,000 79,730 82,782 10/26/23
Ildstad Suzanne Director Director Jun 12 Sell 2.55 44,020 112,251 3,771,392 06/14/23
Ildstad Suzanne Director Director Jun 07 Sell 2.44 141,062 344,191 3,815,412 06/09/23
Ildstad Suzanne Director Director Jun 05 Sell 2.52 33,390 84,143 2,756,474 06/07/23
Ildstad Suzanne Director Director Apr 21 Sell 2.3481 15,004 35,231 2,821,395 04/25/23
Ildstad Suzanne Director Director Mar 01 Sell 2.05 29 59 3,071,366 04/07/23
Ildstad Suzanne Director Director Feb 21 Sell 2.0529 3,500 7,185 3,071,395 04/07/23
Ildstad Suzanne Director Director Feb 16 Sell 2.05 6,551 13,430 3,074,895 04/07/23
Ildstad Suzanne Chief Scientific Off.. Chief Scientific Officer Aug 22 Sell 2.80 525,000 1,470,000 3,081,446 08/23/22
Requadt Scott Chief Executive Offi.. Chief Executive Officer Jul 29 Buy 4.25 39,382 167,374 508,680 08/02/22
Requadt Scott Chief Executive Offi.. Chief Executive Officer Jul 26 Buy 4.25 8,618 36,626 469,298 07/28/22
Requadt Scott Chief Executive Offi.. Chief Executive Officer Jul 22 Buy 3.7497 9,444 35,412 460,680 07/26/22
Nader Francois Director Director Jul 19 Buy 3.62 138,500 501,370 138,500 07/25/22